-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'> The latest public announcement on the Shanghai Stock Exchange Science and Technology Innovation Board shows that Dizhe Medicine has submitted an IPO application to the Science and Technology Innovation Board and was accepted on March 10.
According to the prospectus, Dizhe Medicine adopted the fifth set of listing standards on the Science and Technology Innovation Board this time, and the sponsor (lead underwriter) is CITIC Securities.
The IPO plans to raise 1.
78 billion yuan, mainly for new drug research and development projects and supplement working capital .
According to the prospectus, Dizhe Medicine adopted the fifth set of listing standards on the Science and Technology Innovation Board this time, and the sponsor (lead underwriter) is CITIC Securities.
The IPO plans to raise 1.
78 billion yuan, mainly for new drug research and development projects and supplement working capital .
The IPO plans to raise 1.
78 billion yuan, mainly for new drug research and development projects and supplementary working capital544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;line-height:1.75em;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;color:#B2B2B2;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;'>Screenshot 544px;color:#B2B2B2;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;'>source: SSE Science and Technology Innovation Board official website544px;color:#B2B2B2;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;'>Screenshot 544px;color:#B2B2B2;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:14px;box-sizing:border-box ;overflow-wrap:break-word ;'>source: SSE Science and Technology Innovation Board official website544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Dizhe medicine is administered innovator and AstraZeneca (AstraZeneca), etc.
in 2017 jointly set up of an innovation-driven biopharmaceutical company founder and CEO Dr.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;color:#0070C0;box-sizing:border-box ;overflow-wrap:break-word ;">DZD4205: Specific JAK1 inhibitor544px;color:#0070C0;box-sizing:border-box ;overflow-wrap:break-word ;">DZD4205: Specific JAK1 inhibitor544px;color:#0070C0;box-sizing:border-box ;overflow-wrap:break-word ;"> DZD4205: Specific JAK1 inhibitor DZD4205: Specific JAK1 inhibitor544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>DZD4205 is a new specific JAK1 tyrosine kinase inhibitor.
According to the prospectus, DZD4205 is highly selective for the JAK1 target, but has a weaker ability to inhibit other proteins in the JAK family , so it has better potential safety.
In September 2020, the US FDA granted DZD4205 an orphan drug designation for the treatment of T-cell lymphoma .
DZD4205 is a new specific JAK1 tyrosine kinase inhibitor.
544px;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;'>▲Four products under development of Dizhe Pharmaceutical in the clinical stage (picture source: prospectus)544px;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;'>▲Four products under development of Dizhe Medicine in clinical stage (picture source: prospectus) ▲Four products of Dizhe Medicine under development in clinical stage (picture source: prospectus)544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;color:#0070C0;box-sizing:border-box ;overflow-wrap:break-word ;">DZD1516: HER2 inhibitor544px;color:#0070C0;box-sizing:border-box ;overflow-wrap:break-word ;">DZD1516: HER2 inhibitor544px;color:#0070C0;box-sizing:border-box ;overflow-wrap:break-word ;"> DZD1516: HER2 inhibitor DZD1516: HER2 inhibitor544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>DZD1516 is a highly selective HER2 small molecule tyrosine kinase inhibitor , intended to be developed to treat HER2-positive breast cancer and other HER2-positive solid tumors with or prevent central nervous system (CNS) metastasis .
According to the prospectus, CNS metastasis is one of the most common developments of breast cancer.
The existing core therapeutic drugs and most chemotherapeutic drugs for HER2-positive breast cancer cannot effectively pass through the blood-brain barrier.
Patients with CNS metastasis usually have a poor prognosis.
DZD1516 is a highly selective HER2 small molecule tyrosine kinase inhibitor , intended to be developed to treat HER2-positive breast cancer and other HER2-positive solid tumors with or prevent central nervous system (CNS) metastasis .
According to the prospectus, CNS metastasis is one of the most common developments of breast cancer.
The existing core therapeutic drugs and most chemotherapeutic drugs for HER2-positive breast cancer cannot effectively pass through the blood-brain barrier.
Patients with CNS metastasis usually have a poor prognosis.
A highly selective HER2 small molecule tyrosine kinase inhibitor to treat HER2-positive breast cancer and other HER2-positive solid tumors with or prevent central nervous system (CNS) metastasis544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>DZD1516 is a small molecule drug candidate developed by Dizhe Pharmaceutical that can penetrate the blood-brain barrier .
It has good target selectivity and inhibitory activity.
It can effectively inhibit the proliferation of HER2 breast cancer cells, but has no inhibition on EGFR wild-type cells.
The effect means that the candidate drug may have good efficacy and safety at the same time.
Dizhe Medicine has launched an international multi-center phase 1 clinical trial of DZD1516 against advanced HER2-positive breast cancer with or without CNS metastasis, and it is expected to enter the phase 2 clinical trial in 2022.
DZD1516 is a small molecule drug candidate developed by Dizhe Pharmaceutical that can penetrate the blood-brain barrier .
It has good target selectivity and inhibitory activity.
It can effectively inhibit the proliferation of HER2 breast cancer cells, but has no inhibition on EGFR wild-type cells.
The effect means that the candidate drug may have good efficacy and safety at the same time.
Dizhe Medicine has launched an international multi-center phase 1 clinical trial of DZD1516 against advanced HER2-positive breast cancer with or without CNS metastasis, and it is expected to enter the phase 2 clinical trial in 2022.
A candidate small molecule drug EGFR that can penetrate the blood-brain barrier
